PPD assists clients in isolating the unique challenges associated with psychiatric studies, such as subjective assessments, inter-rater reliability, scale validation and placebo response rates. We consult with clients to quickly create an actionable plan for moving forward to a successful outcome. Over the past five years, we have conducted more than 30 studies from schizophrenia to anxiety, expertly overseeing global programs of all sizes, giving our clients the confidence to quickly bring their drugs to market.
We offer clients a strong mix of sites experienced in these indications supported by a world-class infrastructure, and the capabilities needed to collect performance metrics, including quality of subjective rating scales. Through explicit therapeutic input and training, particularly in the often difficult climate of subjective end points, PPD can help ensure strong data quality and limit placebo response rates.